A5101838218- Cholesterol and Lipid Metabolism
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Lipoproteins and Cardiovascular Health
- Cancer, Lipids, and Metabolism
- Lipid metabolism and disorders
- Peroxisome Proliferator-Activated Receptors
- Drug Transport and Resistance Mechanisms
- Liver Disease Diagnosis and Treatment
- Fatty Acid Research and Health
- Diet and metabolism studies
- Lipid metabolism and biosynthesis
- Adipokines, Inflammation, and Metabolic Diseases
- Diet, Metabolism, and Disease
- Computational Drug Discovery Methods
- Genetic Associations and Epidemiology
- Caveolin-1 and cellular processes
- Atherosclerosis and Cardiovascular Diseases
- Hormonal Regulation and Hypertension
- Antioxidant Activity and Oxidative Stress
- Liver Diseases and Immunity
- Cardiovascular Disease and Adiposity
- Birth, Development, and Health
- Hormonal and reproductive studies
- Bariatric Surgery and Outcomes
- Diabetes and associated disorders
Tufts University
2014-2024
Jean Mayer Human Nutrition Research Center on Aging
2000-2022
GTx (United States)
2019
Framingham State University
2016
Boston University
1988-2013
Radboud University Nijmegen
2009
Tufts Medical Center
1986-2004
Wake Forest University
2004
Hadassah Medical Center
2004
The University of Western Australia
2004
To examine the relationship between elevated levels of lipoprotein(a) [Lp(a)] and coronary heart disease (CHD) risk in a prospective study.Nested case-control study. The cohort consisted participants Lipid Research Clinics Coronary Primary Prevention Trial.Lipid research clinics.The Trial (n = 3806) were men, aged 35 to 59 years, with plasma cholesterol 6.85 mmol/L (265 mg/dL) or greater, low-density lipoprotein 4.91 (190 triglyceride less than 3.39 mmol/L. Subjects randomly assigned either...
BACKGROUND A growing body of evidence from epidemiological data, animal studies, and clinical trials supports HDL as the next target to reduce residual cardiovascular risk in statin-treated, high-risk patients. For more than 3 decades, cholesterol has been employed principal measure associated with low HDL-cholesterol concentrations. The physicochemical functional heterogeneity present important challenges investigators field who are seeking identify effective laboratory methods develop a...
THE SECOND report of the Expert Panel on Detection, Evaluation, and Treatment High Blood Cholesterol in Adults (Adult II, or ATP II) presents National Education Program's updated recommendations for cholesterol management. It is similar to first general outline, fundamental approach treatment high blood comparable. This continues identify low-density lipoproteins (LDL) as primary target cholesterol-lowering therapy. As report, second emphasizes role clinical prevention coronary heart disease...
Apolipoprotein E (apoE) is important in modulating the catabolism of remnants triglyceride-rich lipoprotein particles. It a polymorphic protein with three common alleles coding for apoE2, apoE3, and apoE4. ApoE3 considered normal isoform, while apoE4 associated both hypercholesterolemia type V hyperlipoproteinemia. We quantitated kinetics metabolism 19 normolipidemic apoE3 homozygotes 1 homozygote, compared this 12 homozygotes. In homozygous subjects, was catabolized twice as fast mean...
Apolipoprotein E type 4 allele (apoE epsilon4) is associated with Alzheimer's disease (AD) in the late-onset familial form and sporadic cases, but age-associated risk a randomly sampled elderly population not established. We examined association of apoE epsilon4 AD other dementias (mainly multi-infarct or dementia following stroke) 1,030 persons aged 71 to 100 years population-based Framingham Study cohort. Kaplan-Meier survival analysis revealed that 55% epsilon4/epsilon4 homozygotes...
A unique kindred with premature cardiovascular disease, tubo-eruptive xanthomas, and type III hyperlipoproteinemia (HLP) associated familial apolipoprotein (apo) E deficiency was examined. Homozygotes (n = 4) had marked increases in cholesterol-rich very low density lipoproteins (VLDL) intermediate (IDL), which could be effectively lowered diet medication (niacin, clofibrate). only trace amounts of plasma apoE, accumulations apoB-48 apoA-IV VLDL, IDL, lipoproteins. Radioiodinated VLDL apoB...
Minigel methodology has been utilized for apolipoprotein (apo) E isoform phenotyping and criteria distinguishing the apoE4/4 phenotype (mean apoE4/apoE3 ratio: 5.81) from apoE4/3 1.01) apoE3/3 apoE3/apoE2 2.67) apoE3/2 0.76) based on gel scanning were developed.ApoE allele frequencies in 1209 subjects were: apoE3, 0.786; apoE4, 0.135; apoE2, 0.075; apoE5, 0.002; apoEl, 0.002.Subjects with apoE2 tended to have higher plasma very low density lipoprotein (VLDL) cholesterol lower (LDL)...
A 45-year-old woman with corneal opacification and severe coronary artery disease was noted to have the following plasma lipid levels (mg/dl, +/- SD): total cholesterol 111 13, triglyceride 62 6, very low density lipoprotein 4 1, 106 14, high (HDL) 1 (normal, 50 14). Her two offspring one brother were found HDL values (mg/dl) of 23, 20, respectively. The percentage in esterified form patient's normal at 70%. Lipoprotein electrophoresis showed no alpha band, detectable when subjected analytic...
Our objective was to evaluate the associations of individual apolipoprotein A-I (apoA-I)-containing HDL subpopulation levels with ABCA1- and scavenger receptor class B type I (SR-BI)-mediated cellular cholesterol efflux. subpopulations were measured by nondenaturing two-dimensional gel electrophoresis from 105 male subjects selected various apoA-I in pre-beta-1, alpha-1, alpha-3 particles. ApoB-containing lipoprotein-depleted serum incubated [(3)H]cholesterol-labeled cells measure The...
The apolipoprotein E isolated from plasma of individuals with type III hyperlipoproteinemia (HLP) shows an abnormal pattern when it is examined by isoelectric focusing. Compared to normal subjects, subjects HLP had a decreased fractional catabolic rate in vivo both patients and individuals. delayed catabolism may be responsible for the lipid lipoprotein abnormalities characteristic these patients.
To determine whether lutein supplementation will slow visual function decline in patients with retinitis pigmentosa receiving vitamin A.Randomized, controlled, double-masked trial of 225 nonsmoking patients, aged 18 to 60 years, evaluated over a 4-year interval. Patients received 12 mg or control tablet daily. All were given 15,000 IU/d A palmitate. Randomization took into account genetic type and baseline serum level.The primary outcome was the total point score for Humphrey Field Analyzer...
Data is limited on measures influencing cholesterol homeostasis in subjects at high risk of developing cardiovascular disease (CVD) relative to established factors. To address this, we quantified circulating indicators (plasma phytosterols and precursor concentrations as surrogate absorption synthesis, respectively) Framingham Offspring Study Cycle-6 participants diagnosed with CVD and/or >or=50% carotid stenosis not taking lipid lowering medication (cases, N = 155) matched controls (N 414)....